Subjects -> MEDICAL SCIENCES (Total: 8529 journals)
    - ANAESTHESIOLOGY (120 journals)
    - CARDIOVASCULAR DISEASES (332 journals)
    - DENTISTRY (292 journals)
    - ENDOCRINOLOGY (150 journals)
    - FORENSIC SCIENCES (41 journals)
    - HEMATOLOGY (155 journals)
    - HYPNOSIS (4 journals)
    - INTERNAL MEDICINE (167 journals)
    - MEDICAL GENETICS (58 journals)
    - MEDICAL SCIENCES (2342 journals)
    - NURSES AND NURSING (362 journals)
    - OBSTETRICS AND GYNECOLOGY (207 journals)
    - ONCOLOGY (381 journals)
    - OTORHINOLARYNGOLOGY (82 journals)
    - PATHOLOGY (98 journals)
    - PEDIATRICS (273 journals)
    - PSYCHIATRY AND NEUROLOGY (822 journals)
    - RESPIRATORY DISEASES (103 journals)
    - RHEUMATOLOGY (78 journals)
    - SPORTS MEDICINE (81 journals)
    - SURGERY (401 journals)

RESPIRATORY DISEASES (103 journals)                     

Showing 1 - 104 of 104 Journals sorted alphabetically
Advances in Respiratory Medicine     Open Access   (Followers: 7)
Advances in Thoracic Diseases     Open Access  
American Journal of Respiratory and Critical Care Medicine     Full-text available via subscription   (Followers: 257)
American Journal of Respiratory Cell and Molecular Biology     Full-text available via subscription   (Followers: 20)
American Review of Respiratory Disease     Full-text available via subscription   (Followers: 4)
Angiologia e Cirurgia Vascular     Open Access   (Followers: 1)
Annals of the American Thoracic Society     Full-text available via subscription   (Followers: 17)
Annals of Thoracic Medicine     Open Access   (Followers: 6)
Archives of Pulmonology and Respiratory Care     Open Access   (Followers: 1)
Archivos de Bronconeumología     Full-text available via subscription  
Archivos de Bronconeumología (English Edition)     Full-text available via subscription   (Followers: 1)
Asthma Research and Practice     Open Access   (Followers: 1)
BMC Pulmonary Medicine     Open Access   (Followers: 5)
BMJ Open Respiratory Research     Open Access   (Followers: 6)
Breathe     Open Access   (Followers: 4)
Canadian Journal of Respiratory, Critical Care, and Sleep Medicine     Hybrid Journal   (Followers: 1)
Canadian Respiratory Journal     Open Access   (Followers: 3)
Case Reports in Pulmonology     Open Access   (Followers: 3)
Chest     Full-text available via subscription   (Followers: 102)
Chest Disease Reports     Open Access   (Followers: 2)
Chronic Respiratory Disease     Hybrid Journal   (Followers: 9)
Clinical Lung Cancer     Hybrid Journal   (Followers: 6)
Clinical Medicine Insights : Circulatory, Respiratory and Pulmonary Medicine     Open Access   (Followers: 3)
Clinical Pulmonary Medicine     Hybrid Journal   (Followers: 2)
COPD Research and Practice     Open Access   (Followers: 1)
COPD: Journal of Chronic Obstructive Pulmonary Disease     Hybrid Journal   (Followers: 15)
Current Opinion in Pulmonary Medicine     Hybrid Journal   (Followers: 10)
Current Pulmonology Reports     Hybrid Journal  
Current Research in Tuberculosis     Open Access   (Followers: 3)
Current Respiratory Care Reports     Hybrid Journal   (Followers: 1)
Current Respiratory Medicine Reviews     Hybrid Journal   (Followers: 5)
Der Pneumologe     Hybrid Journal   (Followers: 1)
Egyptian Journal of Chest Diseases and Tuberculosis     Open Access   (Followers: 3)
ERJ Open Research     Open Access   (Followers: 3)
Eurasian Journal of Pulmonology     Open Access  
European Clinical Respiratory Journal     Open Access   (Followers: 3)
European Respiratory Journal     Full-text available via subscription   (Followers: 39)
European Respiratory Review     Open Access   (Followers: 7)
Experimental Lung Research     Hybrid Journal  
Expert Review of Respiratory Medicine     Hybrid Journal   (Followers: 5)
Heart & Lung: The Journal of Acute and Critical Care     Hybrid Journal   (Followers: 13)
Heart, Lung and Circulation     Full-text available via subscription   (Followers: 9)
Indian Journal of Respiratory Care     Open Access   (Followers: 3)
Indian Journal of Tuberculosis     Full-text available via subscription  
Influenza and Other Respiratory Viruses     Open Access   (Followers: 3)
International Journal of Chronic Obstructive Pulmonary Disease     Open Access   (Followers: 3)
Journal of Association of Chest Physicians     Open Access   (Followers: 2)
Journal of Asthma     Hybrid Journal   (Followers: 4)
Journal of Asthma Allergy Educators     Hybrid Journal   (Followers: 4)
Journal of Bronchology & Interventional Pulmonology     Hybrid Journal   (Followers: 4)
Journal of Clinical Tuberculosis and Other Mycobacterial Diseases     Open Access  
Journal of Heart and Lung Transplantation     Hybrid Journal   (Followers: 12)
Journal of Respiratory Medicine     Open Access   (Followers: 4)
Journal of Respiratory Research     Open Access   (Followers: 1)
Journal of Tuberculosis Research     Open Access   (Followers: 1)
Jurnal Respirasi     Open Access  
Karger Kompass Pneumologie     Full-text available via subscription   (Followers: 1)
Kindheit und Entwicklung     Hybrid Journal  
Lung     Hybrid Journal   (Followers: 2)
Lung Cancer     Hybrid Journal   (Followers: 16)
Lung Cancer International     Open Access   (Followers: 2)
Lung Cancer: Targets and Therapy     Open Access   (Followers: 3)
Lung India     Open Access   (Followers: 1)
Multidisciplinary Respiratory Medicine     Open Access   (Followers: 4)
npj Primary Care Respiratory Medicine     Open Access   (Followers: 2)
Open Journal of Respiratory Diseases     Open Access   (Followers: 1)
Open Respiratory Medicine Journal     Open Access   (Followers: 1)
Paediatric Respiratory Reviews     Hybrid Journal   (Followers: 11)
Pediatric Quality & Safety     Open Access  
Pediatric Respirology and Critical Care Medicine     Open Access   (Followers: 1)
Pulmonary Circulation     Open Access   (Followers: 4)
Pulmonary Medicine     Open Access   (Followers: 2)
Pulmonary Pharmacology & Therapeutics     Hybrid Journal   (Followers: 2)
Pulmonary Therapy     Open Access   (Followers: 1)
Pulmonology and Respiratory Research     Open Access   (Followers: 1)
Respiratory Care     Full-text available via subscription   (Followers: 10)
Respiratory Investigation     Full-text available via subscription  
Respiratory Medicine     Hybrid Journal   (Followers: 18)
Respiratory Medicine : X     Open Access  
Respiratory Medicine Case Reports     Open Access  
Respiratory Medicine CME     Hybrid Journal  
Respiratory Medicine Extra     Full-text available via subscription   (Followers: 1)
Respiratory Physiology & Neurobiology     Hybrid Journal   (Followers: 4)
Respiratory Research     Open Access   (Followers: 1)
Respirology     Hybrid Journal   (Followers: 5)
Respirology Case Reports     Open Access  
Revista Americana de Medicina Respiratoria     Open Access  
Revista Chilena de Enfermedades Respiratorias     Open Access  
Revista Inspirar     Open Access  
Revista ORL     Open Access  
Revista Portuguesa de Pneumologia     Open Access  
Sarcoidosis Vasculitis and Diffuse Lung Disese     Full-text available via subscription   (Followers: 3)
Seminars in Respiratory and Critical Care Medicine     Hybrid Journal   (Followers: 14)
Sleep Medicine Reviews     Hybrid Journal   (Followers: 17)
The Clinical Respiratory Journal     Hybrid Journal   (Followers: 3)
The International Journal of Tuberculosis and Lung Disease     Full-text available via subscription   (Followers: 8)
The Lancet Respiratory Medicine     Full-text available via subscription   (Followers: 35)
Therapeutic Advances in Chronic Disease     Open Access   (Followers: 7)
Therapeutic Advances in Respiratory Disease     Open Access   (Followers: 1)
Thorax     Hybrid Journal   (Followers: 38)
Translational Respiratory Medicine     Open Access   (Followers: 1)
Tuberculosis     Hybrid Journal   (Followers: 12)
Tuberculosis Research and Treatment     Open Access   (Followers: 3)
Пульмонология     Full-text available via subscription  


Similar Journals
Journal Cover
Respiratory Medicine : X
Number of Followers: 0  

  This is an Open Access Journal Open Access journal
ISSN (Online) 2590-1435
Published by Elsevier Homepage  [3203 journals]
  • Dual bronchodilators in chronic obstructive pulmonary disease: Evidence
           from randomized controlled trials and real-world studies

    • Abstract: Publication date: November 2020Source: Respiratory Medicine: X, Volume 2Author(s): Antonio Anzueto, Alan Kaplan
  • Methods to improve the yield of right heart catheterization in pulmonary

    • Abstract: Publication date: Available online 27 February 2020Source: Respiratory Medicine: XAuthor(s): Ambalavanan Arunachalam, Neal F. Chaisson, Adriano R. Tonelli
  • Incremental costs of COPD exacerbations in GOLD stage 2+ COPD in
           ever-smokers of a general population

    • Abstract: Publication date: Available online 14 February 2020Source: Respiratory Medicine: XAuthor(s): Marta Erdal, Ane Johannessen, Per Bakke, Amund Gulsvik, Tomas Mikal Eagan, Rune NielsenAbstractObjectivesTo estimate treatment- and productivity-related costs associated with COPD in two different samples, and to analyse the association between the costs and moderate and severe exacerbations.MethodsWe performed a baseline visit and four telephone-interviews during a one-year follow-up of 81 COPD cases and 132 controls recruited from a population-based sample, and of 205 hospital-recruited COPD patients. COPD was defined by post-bronchodilator spirometry. Total costs consisted of treatment related costs and costs of productivity losses. Exacerbation-related costs were estimated by multivariate median regression.ResultsThe average annual disease-related costs for a COPD patient from the hospital sample was nearly twice as high as for a COPD case from the population sample (€26,518 vs €15,021), and nearly four times as high as for a control subject (€6,740). For both sampling sources, the average annual costs of productivity losses were substantially higher than the treatment related costs (€17,014 vs €9,504, €11,192 vs €3,829, and €4,494 vs €2,246, for the hospital COPD patients, the population-based COPD cases, and the controls, respectively). Severe exacerbations were an important cost driver for the treatment related costs in both COPD groups. Moderate exacerbations explained all the costs of productivity losses in the population-based COPD cases, but did not affect the costs of productivity losses in the hospital-recruited COPD patients.ConclusionWe found that there were significant incremental costs associated with COPD, and the treatment related costs were significantly affected by exacerbations. The costs of productivity losses substantially exceeded the treatment related costs in both sampling sources.
  • Asthma, asthma control and risk of ischemic stroke: The HUNT study

    • Abstract: Publication date: November 2020Source: Respiratory Medicine: X, Volume 2Author(s): Aivaras Cepelis, Ben M. Brumpton, Lars E. Laugsand, Arnulf Langhammer, Imre Janszky, Linn B. StrandAbstractBackgroundAsthma, a chronic inflammatory airway disease, shares common pathophysiological mechanisms with ischemic stroke. The aim of the study is to assess the association between asthma, levels of asthma control and ischemic stroke risk in men and women and by smoking habits.MethodsThis prospective population-based cohort study utilized data on 58 712 adults from HUNT Study in Norway free from stroke. Self-reported asthma was categorized as ever asthma, non-active asthma and active asthma (i.e., being on asthma medication within 12 months of the baseline). Asthma control was defined according to the Global Initiative for Asthma questionnaire and was categorized into controlled and not controlled asthma. Stroke was ascertained by linking HUNT data with Nord-Trøndelag hospital records and the Norwegian Patient Registry.ResultsDuring a mean follow-up of 17.3 ± 5.3 years, 2619 participants (4.5%) had a first stroke. Not controlled asthma was associated with a modest increased risk of stroke (adjusted HR 1.34, 95%CI 1.03–1.73). Subgroup analyses revealed that the respective association was stronger among those with history of smoking (HR 1.48, 95%CI 1.10–2.00) and males (HR 1.55, 95%CI 1.12–2.16) while absent in non-smokers (HR 1.02, 95%CI 0.61–1.70) and females (HR 1.05, 95%CI 0.69–1.60). Likewise, active asthma was associated with similar increased stroke risk among smokers and males and absent in non-smokers and females.ConclusionsSymptomatic and active asthma was associated with a modest increased relative risk for ischemic stroke in smokers and males. Future studies should clarify the difference in risks and mechanisms between different phenotypes of asthma.
  • Erratum to “Eosinophils, the IL-5/IL-5Rα axis, and the biologic effects
           of benralizumab in severe asthma” [Respir. Med. X 1C (2019) 100007]

    • Abstract: Publication date: 2019Source: Respiratory Medicine: X, Volume 1Author(s): Andrea Matucci, Enrico Maggi, Alessandra VultaggioThe Publisher regrets that this article is an accidental duplication of an article that has already been published in < Respiratory Medicine: X 1C 100007>, The duplicate article has therefore been withdrawn.The full Elsevier Policy on Article Withdrawal can be found at
  • The effect of dupilumab on lung function parameters in patients with oral
           corticosteroid-dependent severe asthma

    • Abstract: Publication date: Available online 21 November 2019Source: Respiratory Medicine: XAuthor(s): Klaus F. Rabe, Parameswaran Nair, Jorge F. Maspero, Mario Castro, Megan S. Rice, Yamo Deniz, Paul Rowe, Heribert W. Staudinger, Gianluca Pirozzi, Bolanle Akinlade, Neil M.H. Graham, Ariel TeperAbstractBackgroundIn Phase 3 LIBERTY ASTHMA VENTURE (NCT02528214), add-on dupilumab reduced oral corticosteroid (OCS) use while reducing severe exacerbations and improving pre-bronchodilator (BD) forced expiratory volume in 1 s (FEV1) in OCS-dependent severe asthma patients.ObjectiveThis post hoc study evaluated dupilumab's efficacy based on several lung function parameters for the overall population and subgroups defined by baseline biomarkers.MethodsLung function parameters were pre- and post-BD FEV1, pre-BD forced vital capacity (FVC), FEV1/FVC, and forced expiratory flow 25–75% (FEF25–75%). Dupilumab's steroid-sparing efficacy according to FEV1 improvement (≥200 mL vs 
  • Association between blood eosinophils and acute exacerbation of COPD risk
           in patients with COPD in primary care

    • Abstract: Publication date: Available online 19 November 2019Source: Respiratory Medicine: XAuthor(s): Sarah H. Landis, Jeanne M. Pimenta, Shibing Yang, Chris Compton, Neil Barnes, Guy BrusselleAbstractObjectiveWe examined the association between blood eosinophil levels and subsequent rate of acute exacerbation of chronic obstructive pulmonary disease (AECOPD) in a population-based cohort of COPD patients managed in primary care.MethodsThis retrospective cohort study included COPD patients from the UK Clinical Practice Research Datalink linked to the Hospital Episodes Statistics. Patients had ≥1 blood eosinophil count that was not performed within ±30 days of an AECOPD episode. Blood eosinophil counts were modelled as a continuous exposure variable using a fractional polynomial model; the best fitting model was plotted against the incidence rate (IR) of moderate or severe AECOPD per person-year (PY), stratified by AECOPD history and inhaled corticosteroid (ICS) use.ResultsA total of 17,495 patients were included. In the overall cohort, the adjusted IRs of moderate or severe AECOPD increased modestly with increasing eosinophil counts, from 0.80/PY for blood eosinophil levels
  • Long-acting maintenance pharmacotherapy in chronic obstructive pulmonary

    • Abstract: Publication date: Available online 6 November 2019Source: Respiratory Medicine: XAuthor(s): Eneida M. Harrison, Victor KimAbstractExacerbations, which often lead to emergency department visits and hospitalizations, are the main drivers of morbidity and utilization of health care resources among patients with chronic obstructive pulmonary disease (COPD). Appropriate choice of an effective, long-term pharmacotherapy for reducing exacerbations is key to COPD management. In this review, we summarize the available long-acting, maintenance pharmacotherapeutic options for patients with moderate or severe COPD and discuss practical considerations in the management of these patients. Bronchodilators are the cornerstone of pharmacological treatment for COPD, and long-acting muscarinic antagonists (LAMAs) are recommended as initial treatment for most patients with COPD. Dual bronchodilation with a LAMA and long-acting β2-agonist (LABA), with their synergistic bronchodilatory actions, is the mainstay of long-term COPD maintenance pharmacotherapy for patients with high symptom burden, persistent symptoms, or exacerbations. Evidence hints that the effects of different LAMA + LABA combinations may not always be similar, suggesting the presence of an efficacy gradient. However, large-scale clinical trials directly comparing different LAMA + LABA combinations are needed to support or refute this observation. Use of an inhaled corticosteroid in addition to LABA or LAMA + LABA as the initial or follow-up pharmacological treatment is now guided by eosinophil count thresholds. In addition to various medication options, different inhalation devices are available to deliver the medications. When making treatment decisions, medication class, inhalation device, patient and disease characteristics, and patient goals and preferences should be considered.
  • Cost-effectiveness analysis of a single-inhaler triple therapy for
           patients with advanced chronic obstructive pulmonary disease (COPD) using
           the FULFIL trial: A UK perspective

    • Abstract: Publication date: Available online 16 July 2019Source: Respiratory Medicine: XAuthor(s): Melanie Schroeder, Dhvani Shah, Nancy Risebrough, Alan Martin, Shiyuan Zhang, Kerigo Ndirangu, Andrew Briggs, Afisi S. IsmailaAbstractObjectivesThe clinical benefit of once-daily fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) versus twice-daily budesonide/formoterol (BUD/FOR) for patients with symptomatic chronic obstructive pulmonary disease (COPD) has been demonstrated in a clinical trial setting (FULFIL [NCT02345161]). The lifetime cost-effectiveness analysis of FF/UMEC/VI versus BUD/FOR, based on FULFIL data, is reported here.MethodsA previously developed and validated GALAXY-COPD linked-risk equation model was used to assess the cost-effectiveness of FF/UMEC/VI from the UK National Health Service (NHS) perspective. Baseline characteristics and efficacy results from FULFIL and UK NHS reference cost data (2017) were included as inputs. Exacerbation rates (undiscounted), costs, life years (LYs; undiscounted) and quality-adjusted life years (QALYs), and the incremental cost-effectiveness ratio (ICER) were calculated over a lifetime horizon. Costs and QALYs were discounted at 3.5% per year, beyond one year, in accordance with National Institute for Health and Care Excellence (NICE) guidelines. Deterministic and probabilistic sensitivity analyses were performed to evaluate the robustness of the results.ResultsPredicted cumulative exacerbations per patient over a lifetime were 8.393 with FF/UMEC/VI and 10.456 with BUD/FOR. Patients receiving FF/UMEC/VI gained an additional 0.764 LYs and 0.492 QALYs, at an additional mean cost of £1,652, resulting in an ICER of £3,357 per QALY (95% confidence interval: £1,816, £5,194) compared with BUD/FOR. The ICER remained below £6,000 in all but one of the scenario and sensitivity analyses.ConclusionsCompared with BUD/FOR, treatment with FF/UMEC/VI was predicted to improve health outcomes at an additional cost that suggests it would be cost-effective for patients with COPD in the UK.
  • Diagnostic evaluation of bronchiectasis

    • Abstract: Publication date: Available online 15 July 2019Source: Respiratory Medicine: XAuthor(s): Edward D. Chan, William I. Wooten, Elena W.Y. Hsieh, Kristina L. Johnston, Monica Shaffer, Robert A. Sandhaus, Frank van de VeerdonkAbstractBronchiectasis should be considered in anyone with chronic cough and sputum production. High resolution CT is the diagnostic test of choice for diagnosis of bronchiectasis, showing dilated non-tapering bronchi especially into the peripheral lung, increased ratio of the bronchial:arterial diameters, and occasionally mucous plugs within the dilated bronchi. Once a diagnosis of bronchiectasis is made, clinicians must determine whether workup for a predisposing cause is necessary and what diagnostic tests to obtain. Herein, we provide a brief synopsis of the known causes of bronchiectasis with a primary focus on the diagnostic tests that can help uncover an underlying vulnerability to bronchiectasis.
  • Prevalence of lung cancer in chronic obstructive pulmonary disease: A
           systematic review

    • Abstract: Publication date: 2019Source: Respiratory Medicine: X, Volume 1Author(s): Stacey J. Butler, Lauren Ellerton, Roger S. Goldstein, Dina BrooksAbstractBackgroundThere are similar risk factors for the development of chronic obstructive pulmonary disease (COPD) and lung cancer. It is recognized that COPD is common in patients with lung cancer. However, the prevalence of lung cancer in the COPD population remains unclear. We performed a systematic review and meta-analysis to determine the prevalence of lung cancer in COPD.MethodsFour databases (MEDLINE, EMBASE, PubMed, CINAHL) examining the prevalence of lung cancer in COPD were searched for studies published between 1997 and 2018. Meta-analysis with a random effects model was used to calculate pooled prevalence for the included studies. A sub-group analysis was performed for studies of similar population and design. Odds ratios were calculated for case-control studies.ResultsTwenty-one studies that examined the prevalence of lung cancer in a population of 1,682,908 individuals with COPD were included. The pooled prevalence for lung cancer in COPD was 2.79% (95% CI: 1.88–3.88). Results are confounded by significant heterogeneity among studies (Q = 12,622, I2 = 100%), particularly related to the large variation in sample size and study design. Seven studies compared lung cancer prevalence in COPD to controls without COPD with an odds ratio of 6.35 (95% CI: 3.98–10.15).ConclusionsAlthough the prevalence of lung cancer in individuals with COPD is low, it is greater than the prevalence of lung cancer in the general population. Knowledge of the co-occurrence of lung cancer in COPD will inform the screening of lung cancer for patients who have COPD.
  • Could scooting be a useful option for aerobic exercise in chronic
           obstructive pulmonary disease'

    • Abstract: Publication date: 2019Source: Respiratory Medicine: X, Volume 1Author(s): Thomas E. Dolmage, Jacinthe Dubois-Webster, Roger S. GoldsteinBackgroundMany patients with COPD are ventilatory limited and unable to tolerate effective levels of aerobic training. A scooter could be an enticing training modality if muscle activity is partitioned and distal leg muscle activity is emphasized. The aim of this study was to determine whether scooting might emphasize leg heaviness (desired muscle burden), relative to the breathing heaviness, when compared with walking.MethodsParticipants completed two endurance tests, walking and scooting. The intensity for each targeted similar tolerable exercise times (tlimit) simulating comparable training session exposure. Participants scored (Borg0-10) leg and breathing heaviness throughout each test and the slope calculated. Electromyography was used to quantify leg muscle activity.Results15 participants with COPD (mean[SD]: age = 64[11]y; FEV1 = 52[17]%predicted; FEV1/FVC = 50[10]%) completed the study. Successful matching of intensity between modalities was demonstrated by similar tlimit (difference [95%CI] = -0.3[-2.8 to 2.1]min). Scooting resulted in more (60[24 to 95]%) activity of the gastrocnemius in the propulsion and less (−82[-91 to −72]%) in the support leg. Rectus femoris activity was reduced (−68[-95 to −41]%) and increased (117[49 to 184]%) in the propulsion and support leg, respectively. There was no significant difference (0.1[-0.1 to 0.2]) in the relationship between breathing and leg heaviness when scooting was compared to walking.ConclusionsScooting is associated with increased activity of the distal muscles of propulsion of the scooting leg. However, this is offset by the increased activity of the support leg as it resists the rotational force of propulsion, such that the relationship between breathing and leg heaviness is not altered.Graphical abstractImage 1
  • Tocilizumab in sarcoidosis patients failing steroid sparing therapies and
           anti-TNF agents

    • Abstract: Publication date: 2019Source: Respiratory Medicine: X, Volume 1Author(s): Michelle Sharp, Seamas C. Donnelly, David R. Moller
  • T cell Co-Stimulatory molecules ICOS and CD28 stratify idiopathic
           pulmonary fibrosis survival

    • Abstract: Publication date: 2019Source: Respiratory Medicine: X, Volume 1Author(s): Catherine A. Bonham, Cara L. Hrusch, Kelly M. Blaine, Stephenie T. Manns, Rekha Vij, Justin M. Oldham, Matthew M. Churpek, Mary E. Strek, Imre Noth, Anne I. SperlingAbstractIdiopathic pulmonary fibrosis (IPF) is a devastating disease that kills as many Americans as breast cancer each year. This study investigated whether lung function decline and survival associates with adaptive immunity in patients with IPF, specifically the expression of checkpoint molecules ICOS, CD28 and PD-1 on circulating CD4 T cells. Clinical data, blood samples and pulmonary function tests were collected prospectively and longitudinally from 59 patients with IPF over a study period of 5 years. Patients were followed until death, lung transplantation, or study end, and cell surface expression of CD45RO, CD28, ICOS, and PD-1 was measured on CD4 T cells via flow cytometry. Repeated measures of ICOS and CD28 on CD4 T cells revealed significant associations between declining ICOS and CD28 expression, and declining lung function parameters FVC and DLCO, independent of age, sex, race, smoking history, or immunosuppressant use. Strikingly, patients in the highest quintile of ICOS at study entry had markedly improved survival, while those with low CD28 fared poorly. No change in PD-1 expression was found. Analysis of ICOS and CD28 from the first blood draw identified three populations of IPF patients; those at high risk for early death, those with intermediate risk, and those at low risk. These results highlight the role of T cell mediated immunity in IPF survival, finding the assessment of two T cell stimulatory checkpoint molecules, CD28 and ICOS, was sufficient to discriminate three distinct survival trajectories over 5 years of patient follow up.
  • Gender differences in the association between life history of body
           silhouettes and asthma incidence: Results from the SAPALDIA cohort study

    • Abstract: Publication date: 2019Source: Respiratory Medicine: X, Volume 1Author(s): Sofie Hansen, Elisabeth Zemp, Robert Bettschart, Marco Pons, Thierry Rochat, Ayoung Jeong, Dirk Keidel, Christian Schindler, Nicole Probst-HenschAbstractBackgroundThe association of obesity and asthma has been described in children and adults. However, whether a different life course of weight in men and women may explain gender differences in asthma incidence, has not been addressed.ObjectivesUsing data from the Swiss Cohort Study on Air Pollution and Lung and Heart Diseases in Adults, we investigated the role of overweight/obesity as measured by body silhouettes at different life stages in men and women for asthma incidence.MethodsOur analysis included 5417 subjects who were asthma free at age 8, followed up to 2011, and had complete covariate information. The main predictor of interest was self-reported body silhouettes at age 8, menarche, 30, 45, menopause, and 60, and additionally changes in body silhouette number across these different time points. Asthma incidence was defined as newly reported doctor-diagnosed asthma after the body silhouette time point. Asthma incidence and its association with body silhouettes was analysed using sex stratified logistic regression, adjusting for age, atopy, urbanity, smoking, parental asthma, education and study area.ResultsMen at age 60 had an increased risk of asthma incidence per unit increase in body silhouette number (OR 1.93, 95% CI 1.13–3.30). This association was stronger in women at age 60 (OR 2.78, 95% CI 1.49–5.18) and observed also at menopause (OR 1.35, 95% CI 1.03–1.78), as well as per unit change in body silhouette number between age 45 – menopause (OR 1.74, 95% CI 1.15–2.63).ConclusionIn this longitudinal study, the risk of incident asthma increased in men and women with a larger body silhouette in late adulthood. In women, this risk appeared present between age 45 and menopause. At age 60, both men and women were at higher risk of asthma incidence per unit increase in body silhouette, the risk being more pronounced in women. The age-related increase of obesity may underlie gender differences in asthma incidence at higher ages.
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Tel: +00 44 (0)131 4513762

Your IP address:
Home (Search)
About JournalTOCs
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-